You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,250,233


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,250,233
Title:Methods for detecting antibodies
Abstract: Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors.
Inventor(s): Kipps; Thomas J. (San Diego, CA), Messmer; Bradley T. (San Diego, CA), Sanchez; Ana B. (Encinitas, CA), Kummel; Andrew C. (San Diego, CA), Ruidiaz; Manuel (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:12/934,624
Patent Claims:1. A method for detecting an antibody which is not complexed to an epitope of a target protein, said antibody being in a biological sample obtained from a subject which is suspected of containing such antibody, the method comprising: a) synthesizing one or more peptides having a length of about 5-15 amino acids comprising a mimetope recognized by the antibody; wherein the one or more peptides are attached directly on a solid support and wherein said mimetope comprises a linear sequence of amino acids which is different than a linear sequence of amino acids in said epitope of the target protein recognized by said antibody; b) contacting the peptide with said biological sample obtained from said subject; c) allowing binding of the one or more peptides with the antibody not complexed to an antigen to form an antibody-peptide complex; and d) detecting the antibody-peptide complex in said biological sample obtained from a subject.

2. The method of claim 1, wherein detection of the antibody-peptide complex is at antibody concentrations from about 50 ng/ml to about 500 ng/ml.

3. The method of claim 1, wherein detection of the antibody-peptide complex is at antibody concentrations from about 10 ng/ml to about 500 ng/ml.

4. The method of claim 1, wherein the mimetope is identified from a phage-displayed peptide library.

5. The method of claim 1, wherein the mimetope binds to the antigen binding site of the antibody.

6. The method of claim 1, wherein detection of the antibody-peptide complex is performed by detection of a detectable label on the antibody or the peptide.

7. The method of claim 5, wherein detection of the antibody-peptide complex is determined by Western blot analysis, flow cytometry, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), competition immunoassay, dual antibody sandwich assay, chemiluminescent assay, bioluminescent assay, fluorescent assay, or agglutination assay.

8. The method of claim 1, wherein the antibody is alemtuzumab.

9. The method of claim 8, wherein the one or more peptides comprise one or more amino acid sequences as set forth in SEQ ID NOs:1-3.

10. The method of claim 1, wherein the antibody is bevacizumab.

11. The method of claim 10, wherein the one or more peptides comprise one or more amino acid sequences as set forth in SEQ ID NOs:11-14.

12. The method of claim 1, wherein the antibody is rituximab.

13. The method of claim 12, wherein the one or more peptides comprise one or more amino acid sequences as set forth in SEQ ID NOs:4-5.

14. The method of claim 1, wherein the antibody is trastuzumab.

15. The method of claim 14, wherein the one or more peptides comprise one or more amino acid sequences as set forth in SEQ ID NO:15.

16. The method of claim 1, wherein the antibody is zanolimumab.

17. The method of claim 16, wherein the one or more peptides comprise one or more amino acid sequences as set forth in SEQ ID NOs:16-19.

18. The method of claim 1, wherein the biological sample is a fluid.

19. The method of claim 1 wherein the antibody is a monoclonal antibody.

20. The method of claim 1, wherein the solid support is a bead.

21. The method of claim 20, wherein the bead is magnetic.

22. The method of claim 20, wherein the bead comprises magnetic nanoparticles.

23. The method of claim 22, wherein the magnetic nanoparticles comprise iron oxide (FeO).

24. The method of claim 22, wherein the bead has a particle size of about 1 .mu.m to 50 .mu.m.

25. The method of claim 24, wherein the bead has a particle size of about 10 .mu.m.

26. The method of claim 22, wherein the bead further comprises a fluorophore.

27. The method of claim 1, wherein said subject is a human subject.

28. The method of claim 1, wherein said antibody peptide complex is detected at antibody concentrations below 500 ng/ml of said biological sample.

Details for Patent 9,250,233

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2028-03-27
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2028-03-27
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2028-03-27
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2028-03-27
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2028-03-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.